Pirtobrutinib targets ncBTK and can bind to it reversibly, demonstrating efficacy against BTK cysteine 481 (C481)-mutated clones that may emerge during CLL progression following cBTKi treatment. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.